After a momentous 2024, Culver City-based ImmunityBio Inc., the immunotherapy company founded and majority-owned by ...
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Apple (AAPL) ...
ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...
Hosted on MSN6d
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz IntensifiesShares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...
We recently published a list of 10 Stocks Stand Strong Amid Cautious Market Environment. In this article, we are going to ...
Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback